Compare Tango Therapeutics Inc. (TNGX) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Wendys Co — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Wendys Co trades at $6.44 (market cap $1.21B). The key difference: Tango Therapeutics Inc. is far larger — about 3.1× Wendys Co's market cap, and Wendys Co pays a 4.41% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Wendys Co for 78 Days on average.
| TNGX | WEN | |
|---|---|---|
Market Cap | $3.75B | $1.21B |
Volume | 9,619,106 | 3,737,069 |
Sector | Health | Consumer Cyclical |
52-Week High | $32.90 | $9.33 |
52-Week Low | $7.50 | $6.10 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $2.77B | $4.94B |
Dividend Yield | — | 4.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Wendy's stock trades at $6.44, up 2.06% today, but remains near multi-year lows amid ongoing operational challenges. The company shows attractive valuation metrics with a P/E of 9.62 and P/S of 0.55, while maintaining consistent revenue around $2.2B. However, declining net income margins (5.72% in 2025) and a major franchisee bankruptcy highlight significant headwinds. Technical indicators show bearish momentum with the stock trading near key support levels.
While Wendy's valuation appears compelling, the stock faces substantial risks from declining profitability, high debt levels, and competitive pressures. Analyst consensus leans cautious with a $7.58 price target, suggesting limited upside. The recent CEO change and international expansion plans offer potential catalysts, but execution risks remain elevated given the challenging restaurant environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
